PBYI - Earnings call transcript Q1 2024 | Puma Biotechnology, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon. My name is Camilla, and I will be your conference call operator today. [Operator Instructions] As a reminder, this conference call is being recorded.

I would now like to turn the conference call over to Mariann Ohanesian, Senior Director of IR for Puma Biotechnology.

You may begin your conference.

Mariann Ohanesian

Camilla. you, Thank welcome financial and conference to call Good for to the our results XXXX. first discuss afternoon, Puma's quarter of

on Nougues, Officer. Chief are today Officer; and President the the Chief Chief Financial of me Commercial Ludwig, Board Maximo Officer, of and Alan Biotechnology; Puma Jeff Executive Chairman Joining Auerbach, call

via are financial will Investors today, release, presentation call the news at closed news will refer website accessible and market of pumabiotechnology.com. The for That be and our website homepage issued After of our webcast release detailing that days. Jeff replay results. a Puma the sections first to a quarter XXXX slides on next for webcast slides and XX the and available archived this

about that forward-looking in and expectations, and of actual statements Puma's results subject for statements purposes and differ Today's future constitute expressed securities statements risks from conference prospects these laws. Such to events statements. may federal are will plans forward-looking uncertainties, call and include those

discussion time, and to current year XX, For a with for periodic review report Form time filed from XX-K XXXX. of please uncertainties, full December on SEC the the our reports our annual including ended and risks these

after forward-looking You conference any date forward-looking place reliance are to statements, date update or required XXXX. to this obligation of the revise by May undue of except cautioned as Puma as statements which events X, of on not only call, these speak conference live circumstances or law. to the this call, undertakes reflect no

I our to GAAP XXXX to measures. now a our will metrics these Alan. Please release a results. figures. turn not supplement involve GAAP call, our refer measures financial to may may investors our that for substitute to to, call the to a first non-GAAP non-GAAP GAAP refer over today's quarter but to financial reconciliation of news for believe non-GAAP as we During be useful certain We adjustments

Alan Auerbach

in today. NERLYNX revenue includes entirely the call our of in of sales total for joining million from in million thank first QX of royalties the was Product for was quarter our revenue impacted decrease and all from revenue of XXXX and which Thank the by of in below XXXX reported the million Product $X you, reported $XX.X Today, QX you approximately of the net inventory revenue drawdown as specialty of XXXX. and product Puma million $XX.X first consists distributors. was revenue net, for our first in Total of QX Mariann, as and XXXX million Royalty XXXX in million. first QX quarter of a of quarter XXXX. in revenue million reported $XX.X XXXX, $X.X $X was the to compared quarter pharmacies well million $XX which specialty sublicensees. $XX.X XXXX

a from We quarter we that XXXX, reported NERLYNX first decrease of the of XXXX. the inventory in sold of about bottles in bottles his by XXX were details slides. XXX bottles QX QX in bottles. XXXX to Jeff approximately XXXX, comments estimate decreased QX X,XXX sold X,XXX compared XXXX, prescriptions QX new and X% and total QX XX% will provide XXXX. compared were up down prescriptions to approximately In In further

further negatively fourth were and Jeff quarter that third earnings sales in previously NERLYNX our discuss will by in we the decline mentioned impacted this calls. his enrollments in comments.

be XXXX. fiscal these continue responsibility to reduce to net have for to income-positive for shareholders account to to recognize factors expenses We we as continued internal our our

highlights will a follow address Jeff activities. with provide the clinical quarter now on Maximo Nougues on components will quarter, color the will of our I first key statements the NERLYNX of financial commercial then for review Ludwig XXXX.

up was platinum-based cell a CAncer the Phase ALISCA-LungX Alisertib monotherapy through must trial previously treatment PUMA-ALI-XXXX. be and patients have small The BID extensive initiated as first-line on the progressed trial, to we cell X referred that days or will cancer. in announce after dosed at that to for with to of small of trial This cancer trial of stage stage pleased were X we XX-day clinical biomarkers February, Study II In ALISertib alisertib will who Patients be milligrams with can patients provide cycle. immunotherapy. analyzed. extensive tissue-based XX chemotherapy lung XX enroll biopsies so every lung

well perform evaluation an the the analysis Puma for to of plans interim efficacy. as an evaluation of biomarkers as

confirm As the earnings in pathway plays with lung goal with of cancer alisertib II monotherapy a will be call, we last the this on patients small efficacy aurora where our role. discussed cell Phase study kinase of biomarkers the to

we'll be biomarker that efficacy of to in the ALISCA-LungX trial from the would with. randomized the are the If approval paclitaxel Journal believes in of Oncology plus placebo the in seen from these data X efficacy study studies, goal paclitaxel company published the versus engage discuss efficacy would correlate to biomarker FDA subgroups and subgroups was was the that Thoracic XXXX. comparable previously the this in represent a accelerated and plus alisertib strategy in potential it the The to biomarker

enrollment, sites second of in XXXX. approximately expect We anticipate study. the with a to open total to we that contributing from data half this trial have investors and to We in be interim of enrollment for have sites currently share will XX we the able approximately XX

HERX-negative, in a endocrine Phase with in anticipate alisertib combination in II metastatic treatment XXXX. receptor-positive trial QX with the initiation ALISCA-BreastX, also breast We hormone chemotherapy-naïve patients of of cancer

in Phase bundle alisertib in that of endocrine alisertib the remember ASCO published was the We with patients early additionally trial data plus trial hormone, Investors June. XXXX. at versus alisertib metastatic clinical Annual breast II a cancer in JAMA presentations referred will therapy to HERX-negative XX, in XXXX TBCRC therapy as receptor-positive Phase on II was Meeting the anticipate X Oncology which

determine will hormone in this in ASCO breast be of performed HERX-negative, of if trial this biomarkers with part a Annual As correlates to biomarkers. poster of the Meeting. metastatic the trial, any at an biomarker efficacy The data presented XXXX was from alisertib with in patients receptor-positive order cancer analysis presentation

an More have who given is in treated trial was at overcome cell metastatic with of alisertib see osimertinib cell alisertib EGFR-mutant progression, with osimertinib time can non-small there patients are patients addition, lung to ongoing order alisertib metastatic osimertinib to added specifically, with combination investigator-sponsored lung and the osimertinib resistance. non-small cancer EGFR-mutant in in In of cancer.

Interim data drug. the poster on Annual this at also trial was licensing data a trial this the at Updated will in previously presented prior ASCO presentation Puma XXXX Meeting. to on be presented ASCO

with appears last our when kinase call, the of trial pathway of This biomarker to efficacy on has demonstrated have been amended continue have the patients the to added greater about trial, occurs in much osimertinib. half recent biomarker in Based aurora published this in analysis biomarker enrolling patients trial literature biomarker progression patient alisertib which at mentioned this role, on a enrollment time osimertinib of subgroup on this a the population. we where is As limit in consistent with plays a to this a who the has from biomarker earnings the patients on trial to the biomarker. data, only where this

and once the is but to data abstract, publicly. biomarker ASCO look represent note, We poster. presented forward in has not presented another believe investors data it that this potential indication the Of we been will be with discussing in this ASCO for contained might the alisertib,

diversify investor Puma R&D, that in-license As The drugs and to several questions, continues progresses. to would updated on to mentioned potentially the evaluate as on keep leverage and this company commercial prior response in company Puma's earnings allow infrastructure. will regulatory to itself calls and it existing investors

Officer, Chief over turn the Jeff call will during Commercial performance commercial our Puma's to I for quarter. Ludwig, review of now a the

Jeffrey Ludwig

to everyone thanks earnings joining Appreciate call. Thanks, for first quarter and Alan. it, our

commercial Before making I forward-looking reminder just move be into review, a that will the I statements.

the and and customers of where sales significant marketing with adjuvant and to breast increasing on portion targeted teams interactions. promotion. opportunity exist. the treated the nonpersonal in early-stage on in are cancer commercial a sales X% majority patients The than first about reach increased personal greater largely being quarter-over-quarter NERLYNX and XX% both remains the HCP live focused quarter calls team of setting with frequency focused community are HERX-positive extended indication A so

continue evaluate to targeting and data timing more of our try calls and to new overall efficient and effective. We partners make and

to patients the with at higher more efficient commercial the opportunities and and key committed in effective customers risk are and NERLYNX the becoming increase to setting organization. breast We with align awareness identify better need balancing with to are of resources cancer our the trying that is of team around reoccurrence. early-stage the education exists of The needs for unmet broader the goals and looking to

detailed me now the additional will for some specifics a where of call financial transition I review performance. have Let the our I slides I turn Maximo will more commercial finished, around provide results. of Once to to over some

model. distribution an Slide of X our provides overview

specialty and channel has majority do the through model pharmacy business separated specialty channel. channels, of the this the the Now flows not X but distributor channel. changed into see specialty typically remains pharmacy our We distinct quarterly fluctuations, and

In channel QX, business distributor call. our the during This channel. is went what XX% through the we the of unchanged pharmacy QX about essentially specialty and specialty reported our XX% went through remaining earnings from

let will comparisons, $XX.X $XX.X X. Turning million decrease NERLYNX the XXXX million 'XX. reported from a me and million of $XX.X from we was we some impact in information. $XX.X provide to QX which is million, in $X.X changes reported additional Slide XXXX revenue QX decrease of million a Inventory net these so in the QX

we that inventory decreased XXXX, million. about estimate of by QX In $X

estimate As by we in $X.X XXXX million increased about and 'XX. QX QX inventory decreased about comparison, $X.X a that of by million in

QX comparison. provides of quarter-over-quarter ex-factory QX sales X,XXX which quarter-over-quarter Slide of and XXXX, XX% decline. bottle year-over-year a shows In a and XXXX XX% also a and represents bottle were year-over-year sales decline X a ex-factory both NERLYNX

that about first around XXXX. inventory quarter by inventory of in the We again Let changes. more provide me estimate decreased XXX bottles specifics

estimate XXX in As decreased by QX increased XXXX. and a by 'XX XXX in about of we that QX of comparison, bottles about inventory bottles

increase saw and me share some XX% year-over-year. quarter let patient QX, into quarter-over-quarter declined and In metrics additional we about XX% performance. first net NRx, starts, our insights excuse -- or me, new about Now

XX% first quarter-over-quarter Overall a and year-over-year. by quarter of XX% or about about in In terms and prescriptions, total X% year-over-year. decline decreased we demand the X% TRx, quarter-over-quarter saw decline a

into Alan in continue turn patient QX earnings and in new mentioned, As call and as impacted discussed our subsequent enrollments starts enrollments demand QX leading decline patient important new negatively year. drive refills, by QX turn was indicator quarters. starts an which we in the to be last performance into Enrollments

quarter-over-quarter softness largely occurred an but As driven improvement QX. previously discussed, Since time, have in both first we impact team yet seeing. are were part we second X% on quarter-over-quarter about of that increase offset half and did down we is of growth. the currently enrollments that enrollments enough enrollments increased year-over-year. year-over-year in XXXX the not by solely decline of the focused a QX, to driving in The but XX% bottles In saw seen an about in

Turning the X. escalation launch. Slide of highlights X adoption to Slide dose since

is to of discontinuation. grade important start reduced experience that are believe escalation have for significantly lower metric diarrhea and very Patients rate continue We NERLYNX. dose dose a a to lower at will likely that a X

patients In what a QX, benefits in NERLYNX is X feedback remain QX approximately XXXX positive commercial lower dose. escalation continues the the reported we XX% reduced QX ago. from year a higher than at and in dose commercial customers message. that be XXXX This The of to of drug who we received key reported XX% of started than is but

in patients the to received formed setting. opportunities regulatory the NERLYNX Slide for forth was setting to adjuvant In appreciate and officially world. by in efforts extended make Slide approval X. we NERLYNX partners, the the have globe. launched collaborations strategic all the Morocco, We we more X across to Moving Syria around continue put available QX, truly highlights in the extended and also to look in our adjuvant

is to a I'd making their by support in of patients lives difference Puma team commitment. passionate The and their the families colleagues my like thanking up for cancer. and battling about wrap

with its priorities to committed and shareholders. are and being balancing the of long-term efficient more and resources and to effective our We Puma short-term also committed

Maximo? to review turn I results. now our a the call for of over will Maximo financial

Maximo F. Nougues

indication of will note I Please progress I comparisons. of for of QX a quarter a which our with than Jeff. brief believe is our XXXX. first the we XXXX, as financial make comparisons begin summary better Thanks, results commercial year-over-year a to will company that

our our which you I refer and information, will QX more For includes be statements. XX-Q, today that to filed consolidated financial recommend

$X.X of first $X.X expense, per first compensation XXXX. of of a share. remove quarter $X.XX loss which million On quarter million the adjusted for a XXXX, million a the of non-GAAP net stock-based GAAP income basis, loss to or reported $X.XX compares we to in XXXX net we share the of For is QX reported impact per net on of share. $X.XX or $XX.X per based This or

$XX.X million NERLYNX Gross QX revenue QX in XXXX. million sales XXXX and from was in $XX.X

NERLYNX a Alan million, mentioned, was million from XXXX. $XX.X QX $XX.X sales As product in net revenue decline reported from

were adjustment our in and distributors sales lower Royalty totaled QX million versus of in enrollments the in XXXX. well XXXX. to of QX. $X net gross in $X.X net as million revenue to by buildup drawdown million as in QX compared impacted approximately by was QX higher QX $X.X QX XXXX million approximately first quarter in Inventory $XX QX

reflected As our quarter. expected, partner as versus the to timing of we in QX noted shipments lower royalties China, last

increase copay higher in the the net about net million, gross sales in QX intangible adjustment gross Our was to QX $XX.X amortization QX drivers compared Cost of was $X.X related to main our adjustment government reported XXXX. XXXX of license. versus to and XX.X% QX Higher XX.X% of neratinib the were Cost chargebacks was QX for million for sales XXXX assets million. the XXXX. $XX.X including for of to XXXX

Going quarter cost as forward, the of to sales. of licensor to milestones continue amortization we million of $X.X recognize about per will

in NERLYNX For fiscal year will anticipates the to million $XXX the Puma range of product $XXX be million. XXXX, revenue net

XXXX on that anticipate of full our be higher between higher XX.X% for remittance ]. Medicaid XX.X%, net We year due expected also will the gross than adjustment to reduction and inflation impact the [ to the XXXX

to around $XX from the the the year anticipate In million of we our range addition, $XX fiscal receiving for million. in world XXXX, partners royalties

license We in the to XXXX revenue range $X million $X of in million. expect

income in the to for million also full net of that range million. the will We expect year be $XX $XX

of in will of no to We $XX anticipate range anticipate that we license range will million. Also, million, revenues we revenue be product the $X to QX million for QX million XXXX, in be royalty NERLYNX net expect revenue. the $X.X and $XX

but we XX%. other further be higher QX full We in be expenses expense, litigation will expect in will any in well Due and approximately gross the our a to expenses to estimate remainder these QX that to $X a XXXX the QX we forecasting net between million. $X of XX% net income-positive loss net of loss XXXX. are a quarters alliterative we and net to and that adjustment million QX year. anticipate as XXXX items, as for the onetime in anticipates Puma Puma for Due

million of were SG&A charges for XXXX SG&A $XX.X from million of for stock-based the XXXX, $X.X $XX.X down in first of compared to QX fourth million quarter expenses the QX XXXX. million $X.X XXXX. quarter noncash expenses for included compensation in

Research $XX.X first compared development quarter quarter of compensation million included the noncash XXXX. fourth the in in the of in of fourth from first $X.X million $XX.X XXXX, expenses expenses to for charges R&D the were million quarter unchanged of XXXX of quarter and stock-based XXXX.

expenses we our higher Puma expect XX% side, compared expense anticipate in be the to than flat specifically, and Due future XXXX to On litigation SG&A quarters. X% More to increase XX% expenses XXXX. year-over-year. R&D operating to total we decrease anticipates XX% to QX to expenses, expenses expenses to in to G&A in significantly by

cash the of equivalents At XXXX, year-end In approximately at approximately versus million cash QX approximately cash reported million $XX $XXX million. we first and of Puma in earned cash, in compares This XX, $XX.X securities XXXX. earned million XXXX, quarter had of marketable of March about $XX.X XXXX. to

receivable Our million. was balance accounts $XX.X

approximately of receivable sales range XXXX, inventory. our We that days are distribution our XX outstandings network March XX, between accounts estimate weeks XX of XX Our terms while maintained X about and days. as days

of to of earnings, to alisertib commercialization our controlling continue focus and on expenses. deploy financial Overall, development our resources the we

Alan Auerbach

senior Directors with its focused continue on recognizes Maximo. Board to income. cooperation NERLYNX in its sales net and remain to beyond the management Thanks, Puma's in continues and shareholders of trends maintain positive to XXXX to responsibility fiscal

to from order also performed reducing to seen for major full guiding the In the the reductions flows. expense are XXXX, reduction that income expenses positive we positive in that a XXXX. cash fourth is of believe that these net net in the that the to income quarter contributor continue expense goal expenses a reductions. and of the company perform with resulted implemented XXXX previously we maximize have The We to was operational year in

this we'll committed continuing needed and income future. We remains company updating The continue in look to this to reduce net the positive on expenses forward if achieve achieve to this. to to investors

cancer ways effective their we battling to goal. that cancer, during a We solid remain about patients There will for tumors. achieve to lung these strive more finding unmet other significant at and and patients at breast are continues to Puma journey, committed helping and continue passionate need

concludes today's presentation. This

to We will operator floor back now Operator? the turn the for Q&A.

Operator

the first Ed [Operator Your from Wainwright. H.C. with comes line Instructions] question of White

Edward White

strategy a actually. big picture question A just on So sales. question,

Alan You've SG&A to are be year. the cutting costs. and down efficient while you're be promotion said just your sales Jeff, in for able -- wondering past, that going -- and to the drug target becoming promotional-sensitive and your how expenses more is also I'm the improve to are of going

Jeffrey Ludwig

Ed, it. do this We is yes, appreciate believe promotionally I drug sensitive.

And talked and trying as find efficiencies about. so we're we effectiveness to

attention my is which able We're One do of also, expanded our to nonpersonal opening, voice. we're I generate promotion, is as the cost-effective a way share ways of that that trying of to fairly mentioned we've we're in organization. the evaluating and of ways find reach goals to nonpersonal, as costs with number our a and our large personal both paying partners the of well expanding of frequency, associated competitive to cost-effective, while

Alan Auerbach

more much well. was to effective of as that. this impact more cetera. it's both We quite of as cost looking the things and sales, analysis and its in Jeff at business of And enrollments aspects promotion which on and contribute recent promotion like a Ed, terms et And did actually Alan. the nonpersonal And personal Yes. effective mentioned, kind levers nonpersonal the is

and So we also nonpersonal while decreasing I increasing think increasing we promotional increase costs. are of voice sensitivity promotion, as share

Jeffrey Ludwig

Ed, hard personal add to lend us go better ROI. little monetized that is I'd decisions promotion, the a in worked being try back And really community. a color. to in the those cases many to around the bit right Even and and make is which more access evaluate opportunities We've much

they past. of farther So those asking choices as and and our part go field of in business efficiency. have teams the we're trade-offs make our to than owners to big leaders to allow our dollars the That's a much

Edward White

to wanted by lower mention lower dose numbers starting the of continually just lower to wouldn't as back lower that that because you or around -- discontinuation. go higher a dose, I be the of effects, you starting you capturing put the staying time a Great. you're patients rate any starting when weren't refills Can you drug that having at there'll number capturing side on you're of before far that length are dose? as that the that

Jeffrey Ludwig

Ed, great question.

there's of been I a in things. think the past. much now couple from better there's say, would this than One, overall, I a of molecule understanding customers

can controlled there's a up around moving or We see plus about is data low minus based starts So new as on we going believe ways X%, we way and somewhere guess report, X starting patient of that. to do it. you there. the right And XX%

month, lower persistence dose. at with a to look about around any have I XX% more As patients on they we start X% if drug curves a given

basis, month that given on a lower but high. those regular do fluctuations, opposed we Now for increased those any started as is so low those that and to discontinuations on cohorts started monitor there we see

do same a and the high customers the -- do I suggests better But achieve that dose well, reduce end data customers can does there our to they way. lower as add here. dose will start persistence are you simply say and the that the

Alan Auerbach

is, low managing I HCPs start other the add do is of high this dose. a number to the there of the the don't would are need side okay feel Ed, that effects who they And so dose, to part a when they drug at they're

don't, roughly who don't can just they this XX% the at XX% have need think feeling to XX% manage it, I the a versus to. don't, have at So if dose who I low I the the juncture, of start who I look

Edward White

Okay. your or And potential are, us few is my the you your what you've you in-license? partners in-licensing on for last development. mentioned Can drugs potential just benchmarks just target potential tell as last and to question hurdles are quarters, business

Alan Auerbach

to Yes. Ed. Happy that, do

sales So that force look, have targets cancer. we happen breast specifically to a commercial

from focus, so Obviously, a that, a will. to drug the if it's whether can asset. that's anything clinical or one commercial obviously kind most that's of the you that that makes both channel we add focuses And a on -- sense,

commercial you of get net if can wide it use to a obviously, it's is at to something our And would if we adding economies want the EPS-accretive, from it which perspective, like casting that. to Happy in obviously, that sales to scale, do. asset, that force a of kind we can We're be do existing what look things will.

molecule. Again, the on Something that's more something breast of R&D sense. focused an most the space makes

So that. be things targeted tend it's on that to

do in treat obviously, they the also tend setting, community sometimes to lung. breast Now and you see that

make assets well. lung sense cancer as from that obviously, perspective So

Operator

of Our line Rao Cowen. question TD comes from with the next Divya

Divya Rao

This Divya Mark. for I quick trials. question had just the on a is on alisertib

and explore planning Phase then a trial, Specifically forward? first to metastatic the are breast kind biomarker for II guys post planning on are on option figure [indiscernible] doing hoc a of Or alisertib? the running there you strategy you cancer to

Alan Auerbach

question. Yes, you thank the for

drug. the RB-X, such know previously and in efficacy the role, ones to where to we cancer that's We we we When saw strategy. things lung know cell employ plays are that biomarkers that trial, of biomarker kinase and clear are of involved we that pathway, that shown, that like a kinase in-licensed the made the alisertib, looking the aurora we definitely aurora very the due where small we've certain best there one a was as c-Myc

in HR-positive, that breast definitely indication. the the HERX-negative We are in looking to study do

the of probably those to we we still can biomarkers. would do some is clinical from try a analysis for that's ongoing. the now, In waiting what enrich there's trial, right We're for types that. to those of get finalize terms clues trial, In where biomarker results

the kinase as There's So potential would of ones in anything be cetera. it's pathway. a would very et lot I again, the c-Myc, Admittedly, involved pathway. a RB-X, broad say aurora ones such

is likely it would So biomarker-focused a after and enrich those go for biomarkers we indication.

Divya Rao

And interactions to How think those I live one the guess close quick how would interactions for pre-COVID live then helpful. question returning levels? the you, are you That's NERLYNX. -- on do

And then you the previous follow-up on focus on kind Or promotion more non-personal for of increasing in are a Is question. the that promotion? terms of guys a you focused primarily?

Jeffrey Ludwig

Both, I nonpersonal, would for we And being restricted be area. great say Oncology therapeutic Divya, small right? it a so question. want restrictive to more itself as a increase and company, both personal a relatively well. can us is

So increase nonpersonal. we personal and in want to see both an

give So some you color let more me there.

virtual, live to about asked we virtual. in first this versus You around versus XX% quarter. XX% live that are live We've XX%, been XX% about

mix same. Prior I interactions much limited XXs live higher going the COVID, think in relatively we is virtual. to in very that were stay to with of terms high the

smaller a are company. We

territories. large have teams sales our So

efficiencies that's of the like. So we part

have very ways can hard virtual can have I also live we're being and good we efficient Ed increase virtual increasing efficient travel one spend. earlier both working and more the effective with asked an the the you calls, know well. and to an as If around that's access If that of calls about effective we're engagement, call, me

Alan Auerbach

Alan. is this Divya,

virtual interactions. pre-COVID, that technologies we question have lot of technologies of In for we and the a have now didn't remember terms implementation of really pre-COVID, your those of

XX% used mentioned, pre- or why they our Jeff weren't is live. things which Zoom and of most much, just Teams like COVID that, interactions really like things was So being XX%,

calls continue quarter-over-quarter. In increase. mentioned focus, in Jeff for of number live is first which HCP that one to We're terms hoping as calls script, to increased in the X% his the quarter

we no or an it interactions efficient. way, are our which looking at effective more more in or our So is personal shape perspective, and promotion looking decrease from live just to form, investment one

Jeffrey Ludwig

pulls really And live cast in hope manner. some it the very into a cost-effective allows our of promotion us the broad people interactions net with to a very that nonpersonal

Operator

Wang question from line Gena with next our of Barclays. the comes And

Unknown Analyst

on Tony Gena. for This is

kind in the What on be one expect quick to biomarkers. the data determined or would in one how we signal? of used decisions consider Just for a should the order be this And for positive to development.

Alan Auerbach

Thanks for Tony. the question, Yes.

significant cell loss c-Myc in lung statistically the was and that OS published small trial, trial You'll mutation would I was to in which PFS biomarkers. RB-X, function cancer biomarkers, Thoracic amplified, in a in those increase the it and specifically so the Journal That's remember Oncology, you the of be saw and something was randomized the consider a positive.

seeing it the Something the of where you're from rest patients. that differentiates

a I So this would more biomarker vast one, analysis. say they're in doing much

to would a say PFS, ORR suggest terms in biomarker in rises that kind patients will, aurora playing if look see. up, of you anything that there I either is kinase So that or is would of some would getting role That's showing in where you're that better activity driving that cancer. what we

Operator

to conference And for turn back Mariann question-and-answer This session. that, with like to would the closing I concludes remarks. our

Mariann Ohanesian

us all today. for you Thank joining

be pumabiotechnology.com reminder, via today. may beginning evening. a later a Have the replay call good As accessed at of this webcast

Operator

our for gentlemen, a today's participating conference and in concludes thank you day. great program. Ladies Everyone, This have call.

You now disconnect. may

Puma Biotechnology (PBYI) 2 May 242024 Q1 Earnings call transcript